• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
  • Contact
  • About
Sunday, July 3, 2022
Maryland Digital News
  • Home
  • US
  • Business
  • World
  • Baltimore
  • Columbia
  • Germantown
  • Waldorf
  • Silver Spring
  • Frederick
  • Press Releases
  • Videos
No Result
View All Result
  • Home
  • US
  • Business
  • World
  • Baltimore
  • Columbia
  • Germantown
  • Waldorf
  • Silver Spring
  • Frederick
  • Press Releases
  • Videos
No Result
View All Result
No Result
View All Result
Home Silver Spring

United Therapeutics Corporation To Report Fourth Quarter And Full Year 2021 Financial Results Before The Market Opens On Thursday, February 24, 2022

by NewsReporter
February 21, 2022
in Silver Spring
Reading Time: 3 mins read
united-therapeutics-corporation-to-report-fourth-quarter-and-full-year-2021-financial-results-before-the-market-opens-on-thursday,-february-24,-2022
Share on FacebookShare on Twitter

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Feb 21, 2022–

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2021 financial results before the market opens on Thursday, February 24, 2022.

United Therapeutics will host a public webcast Thursday, February 24, 2022, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics’ website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one week and can be accessed at the same location.

United Therapeutics: Enabling Inspiration

We build on the strength of our research and development expertise and a distinctive, entrepreneurial culture that encourages diversity, innovation, creativity, sustainability, and, simply, fun. Since inception, our mission has been to find a cure for pulmonary arterial hypertension and other life-threatening diseases. Toward this goal we have successfully gained FDA approval for five medicines, we are always conducting new clinical trials, and we are working to create an unlimited supply of manufactured organs for transplantation.

We are the first publicly traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. At the same time, we seek to provide our shareholders with superior financial performance and our communities with earth-sensitive energy utilization.

You can learn more about what it means to be a PBC here: unither.com/PBC.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements relating to our mission to find a cure for pulmonary hypertension and other life-threatening diseases, our ongoing and future clinical trials and other research and development efforts, and our goals of furthering our public benefit purpose, providing superior financial performance for shareholders, and providing our communities with earth-sensitive energy utilization. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of February 21, 2022 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

View source version on businesswire.com:https://www.businesswire.com/news/home/20220221005093/en/

CONTACT: Dewey Steadman at (202) 919-4097

Email:[email protected]

KEYWORD: NORTH CAROLINA MARYLAND UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH OTHER HEALTH CLINICAL TRIALS PHARMACEUTICAL CARDIOLOGY BIOTECHNOLOGY

SOURCE: United Therapeutics Corporation

Copyright Business Wire 2022.

PUB: 02/21/2022 06:00 AM/DISC: 02/21/2022 06:02 AM

http://www.businesswire.com/news/home/20220221005093/en

Copyright Business Wire 2022.

Read More Here

Related Posts

5-things-to-know-today,-april-14,-in-montgomery-county

5 Things To Know Today, April 14, In Montgomery County

by NewsReporter
April 14, 2022
0

It’s Thursday, April 14 and here are five things to know in Montgomery County. 1. State of the County: Montgomery County Executive Marc Elrich will deliver his 2022 “State of the County” address at noon at the Silver Spring Civic Building. This will be County Executive Elrich’s first in-person State...

senator-demands-answers-from-fda

Senator Demands Answers From FDA

by NewsReporter
April 13, 2022
0

U.S. Sen. Patty Murray (D-WA), Chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee, sent a letter to Food and Drug Administration (FDA) Commissioner Robert M. Califf urging answers and immediate action following a Politico report that lays bare a culture of delay and inaction in the agency’s...

what-le-pen-would-(and-wouldn’t)-do-if-she-beats-macron

What Le Pen Would (And Wouldn’t) Do If She Beats Macron

by NewsReporter
April 12, 2022
0

FRENCH TWIST — If Marine Le Pen becomes the next president of France, the European Union won’t collapse. Neither will the euro. There isn’t going to be a Frexit.But the far-right politician is a genuine threat to the liberal Western order. Here’s why you should worry she could win France’s...

ville-valo,-ex-him-lead-singer-announces-2023-us-tour

Ville Valo, Ex-HIM Lead Singer Announces 2023 US Tour

by NewsReporter
April 11, 2022
0

(CelebrityAccess) – Former HIM frontman Ville Valo (VV) has announced a 2023 tour of the United States supporting his album Neon Noir. The Finnish singer/songwriter has confirmed his next album will be released in early 2023. In addition to the announced US dates, VV will also be hitting Europe and...

Maryland Digital News

© 2021 Maryland Digital News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
  • Contact
  • About

Follow Us

No Result
View All Result
  • Home
  • About
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Maryland Digital News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT